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Abstract
In the last few years, there has been increasing interest in the physiological role of acylation-stimulating protein (ASP). Recent studies in
rats and mice, in particular in C3 ( / ) mice that are ASP deficient, have advanced our understanding of the role of ASP. Of note, the
background strain of the mice influences the phenotype of delayed postprandial triglyceride clearance in ASP-deficient mice. Administration
of ASP in all types of lean and obese mice studied to date, however, enhances postprandial triglyceride clearance. On the other hand,
regardless of the background strain, ASP-deficient mice demonstrate reduced body weight, reduced leptin and reduced adipose tissue mass,
suggesting that ASP deficiency results in protection against development of obesity.
In humans, a number of studies have examined the relationship between ASP, obesity, diabetes and dyslipidemia as well as the influence
of diet, exercise and pharmacological therapy. While many of these studies have small subject numbers, interesting observations may help us
to better understand the parameters that may influence ASP production and ASP action.
The aim of the present review is to provide a comprehensive overview of the recent literature on ASP, with particular emphasis on those
studies carried out in rodents and humans.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
In recent years, it has been widely recognised that
adipose tissue constitutes not only a storehouse for energy
in the form of triglyceride, but is also a metabolically active
organ producing numerous secreted proteins, enzymes and
hormones. Within the ever-proliferating list of autocrine and
endocrine hormones produced by adipose tissue, acylation-
stimulating protein (ASP) has been recognised as a member
of this family of proteins. In fact, a number of recent
reviews on adipose tissue hormones highlight the major
functional properties of ASP in regulation of adipose tissue
triglyceride storage [1–5].
The aim of the present review is to present a compre-
hensive summary of the physiological studies on ASP and
the related proteins: complement C3, factor B and adipsin in
humans and rodents. We will review the physiological
studies available in rodents (rats and mice), with a particular
emphasis placed on studies in C3 knockout (KO) (ASP-
deficient) mice. Finally, we will attempt to integrate the
physiological data available in humans for each of these
plasma proteins in relation to metabolic disorders: obesity,
cardiovascular disease, diabetes and dyslipidemia.
1.1. Identity of ASP
ASP is identical to C3adesArg [6,7], and is produced
through a two-step process (see Fig. 1) involving three
proteins of the alternate complement system: C3, factor B
and adipsin, all of which are synthesised and secreted by
adipocytes [7,8]. ASP is generated through interaction of C3
with factor B and the enzyme adipsin (a.k.a. complement
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factor D) resulting in (i) cleavage of the parent protein,
complement C3 to generate C3a followed by (ii) desargi-
nation of the carboxyl terminus to generate C3adesArg
(ASP). While the function of C3a as an immune modulator
in myeloid systems has been well documented, C3adesArg
(ASP) appears to be inactive in those systems [9]. Carbox-
ypeptidase B, produced by many cells (including fibro-
blasts), is present at high levels in plasma and only ASP
(and not C3a) is found circulating. On the other hand,
because C3a as well as ASP both appear to be potent
stimulators of triglyceride synthesis in adipocytes and
preadipocytes, conversion is not necessary for action [7,9].
While X-ray crystallography and NMR analysis of C3a
and C3adesArg (ASP) did not detect any major differences
in those areas for which resolution was possible, analysis of
the carboxyl terminal flexible tail of the molecule (wherein
lies the amino acid difference) was not possible [10,11]. In a
recent study, we demonstrated that there were clearly differ-
ences in the structural requirements of the protein which
were important in producing the immunologic effects on
myeloid cells vs. the triglyceride synthetic effects on fat-
storing cells [9,12]. For example, while the carboxyl termi-
nal arginine appears to be essential for immune function of
C3a, there appears to be no requirement for the terminal
arginine for triglyceride synthesis [9]. Moreover, the tightly
coiled core region of the molecule, which contains three
disulfide bridges, is important for triglyceride synthetic
activity; by contrast, this core region is not required for
immunologic activity [12].
These studies suggest that the potential differences may
well lie in the nature of the receptor interaction. While a C3a
receptor has recently been identified [13,14] and has now
been cloned in human, mouse and rat [13–16], neither C3a
receptor protein nor mRNA appears to be present in adipose
tissue as determined by Northern blot and immunofluores-
cence (unpublished data). On the other hand, ASP/C3ade-
sArg has been shown to bind specifically and saturably to
subcutaneous and omental adipocytes [17], preadipocytes
[9] and fibroblasts [18] in human and murine cells, suggest-
ing the presence of an alternate, as yet uncharacterised,
receptor mediating the effects of ASP.
1.2. Role of ASP
ASP increases triglyceride synthesis in fat-storing cells
[19]. The effect is achieved through stimulation of fatty
acid incorporation into adipose triglyceride (FIAT) and
increases in glucose transport. Glucose transport is
increased through enhanced translocation of glucose trans-
porters (Glut1, Glut3 and Glut 4) to the plasma membrane
surface. While our studies have focused on humans and
mice, there is now additional evidence that ASP-like
proteins may influence fat storage in cows [20], pigs [21]
and even plants [22]. A recent paper by Van Harmelen et
al. [23] contributes importantly to understanding ASP func-
tion. Not only does ASP increase lipogenesis in adipocytes,
but ASP also inhibits hormone-sensitive lipase (HSL)-medi-
ated lipolysis.
For both FIAT and glucose transport, the effects of ASP
are additive and independent of those of insulin [24–26], a
well-recognised lipogenic hormone. In the studies by Van
Harmelen et al. [23], in the presence of both insulin and
ASP, the combined effect was a reduction in net fatty acid
output from the adipocytes, with almost complete (97%) re-
esterification and storage of the fatty acid available. Thus, in
combination with insulin, ASP can provide a powerful drive
for fat storage, at least in isolated cells. These functional
data have led to increased interest in ASP, in particular in
evaluation of plasma ASP in humans and rodents.
1.3. Regulation of adipose tissue production of C3 and ASP
While it has traditionally been assumed that the liver is
the primary site of synthesis for C3 [27], it has since been
demonstrated that a number of cells are competent for both
C3 and factor B [28] synthesis. Recently, it has been clearly
demonstrated that human adipose tissue can also synthesise
and secrete C3 and factor B in a differentiation dependent
Fig. 1. Conversion of C3 to ASP: C3 converts spontaneously to activated C3*, a C3b analog which then combines with B to form C3*B. Adipsin then cleaves
the bound B to generate C3*Bb and Ba. C3*Bb is the active convertase that cleaves C3 to C3a and C3b. Carboxypeptidase B (CpB) cleaves the N-terminal
arginine of C3a to produce ASP. The generated C3b can combine with B to start another cycle. The enzymes adipsin, C3*Bb (or C3bBb) convertase and CpB
are indicated in boxes.
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manner [7,8]. It is widely recognised that in humans, adipsin
is primarily made in adipose tissue [29], although recently
shown that liver [30,31] and macrophages [32] may produce
small amounts. Thus, while the C3 cleaved to generate ASP
may not be derived from adipose tissue, the adipsin required
for enzymatic action almost certainly is. Considering, how-
ever, the strong relationship between C3 and ASP with
obesity (see below), adipose tissue may well produce a
considerable amount of total body ASP.
It should be pointed out that ASP (C3adesArg) is not
only produced through the interaction of C3, factor B and
adipsin in the alternate complement pathway, but ASP
could, potentially, be generated through the two other
complement pathways: the classical and the lectin pathway.
While adipsin was first recognised based on its expression
in murine adipose tissue, multiple proteins from the alter-
nate complement pathway are also produced by adipose
tissue [33–36]. These include C3, B, factor H, factor I,
properdin, Crry and complement receptors CR1 and CR2.
Some of these are increased during differentiation of
adipocytes (C3, adipsin), others decrease (factor H and
Crry), and some remain constant (factor I, properdin, CR1).
Any of these changes might influence ASP production, but
this remains to be examined in future studies. However,
because adipocytes do not appear to produce either C2 or
C5 (both essential for the classical pathway) or any other
complement factors required for the cell lysis pathway [34],
it appears that the adipocyte possesses exclusively the
proximal components of the alternate pathway, and ASP
is likely to be formed in the microenvironment of the
adipocytes [19].
The production of C3 and ASP was further examined
in human studies. While the conversion of C3 to ASP
may be regulated by posttranslational regulatory factors
(as discussed later), the level of ASP may also be
influenced by the concentration of its precursor, C3 or
the initiating enzyme adipsin (see below). Three very
recent studies have demonstrated the presence of C3
mRNA in subcutaneous [37–39] and omental [38] adi-
pose tissue. C3 expression has been reported to be
increased in older vs. younger subjects (n = 29 subjects,
Ref. [37]) and in omental vs. subcutaneous tissue (n = 9
subjects, Ref. [38]). Dusserre et al. [38] suggested that
ASP (in fact C3) gene expression was increased in
omental fat as a compensatory phenomenon to counteract
the greater lipolytic capacity of the visceral cells. A
similar argument is used by Imbeault et al. [37] to explain
the apparent contradictory finding that HSL activity was
lower in older vs. younger subjects, in spite of increased
expression of HSL mRNA. They suggested that increased
C3 mRNA will result in increased production of ASP,
which would inhibit HSL activity (as discussed above)
and explain the apparent decreased lipolytic activity in the
face of increased mRNA for HSL.
Surprisingly, although ex vivo secretion of adipsin from
human adipose tissue was described a decade ago [40], we
could only find a single study examining adipsin in human
adipose tissue [41]. In that study (n= 12 subjects), also
surprisingly, there was no correlation of adipsin mRNAwith
body mass index (BMI), no difference between omental and
subcutaneous tissue, and no difference between males and
females. However, considering the limited data available,
our knowledge would benefit from a more thorough study
of all factors (C3, factor B and adipsin) in an expanded
population.
We have examined direct ASP production in human
subcutaneous adipose tissue [42,43]. In control subjects,
while ASP in the general circulation remained relatively
stable, ASP efflux from an abdominal subcutaneous adi-
pose tissue site increased postprandially from 3 to 5 h, over
the same time period when chylomicron triglyceride clear-
ance and fatty acid flux into adipose tissue were maximal
[42]. In fact, when FIAT over the 6 h was calculated, it
correlated directly with the production of ASP. Interest-
ingly, while insulin levels also increased over this same
postprandial period, and certainly contributed to adipose
tissue FIAT, insulin did not correlate with FIAT, while ASP
did [42]. At fasting, however, there was no net production
of ASP. This contrasts with ASP production in obese
subjects which was greater than control at all time points
and was increased even at fasting [43].
With the many factors that change postprandially or in
insulin-resistant states such as diabetes, it is difficult to
pinpoint exactly which component might be responsible for
the stimulation of C3 and ASP production. Experiments
with cultured human adipocytes have demonstrated that
insulin (to a moderate degree), but especially chylomicrons,
appear to stimulate both C3 and ASP production [44–46].
On the other hand, Koistinen et al. [39] showed that a
euglycemic (4 h) hyperinsulinemic clamp had no effect on
C3 mRNA levels. C3 mRNA did correlate with BMI,
glucose disposal rate, plasma triglyceride, non-esterified
fatty acid (NEFA) and leptin (n = 12 subjects) [39]. We
speculate, therefore, that ASP production may be up-
regulated in insulin-resistant states, perhaps by one of the
factors listed above.
A recent article demonstrated that diets containing
differing types of fat (polyunsaturated vs. trans fatty acids)
have been shown to influence fasting ASP levels after
several weeks feeding in hypercholesterolemic women
[47]. While the exact mechanism is unknown, several
components of chylomicrons may have an effect, one of
these being the amount of retinoic acid being delivered to
the cell which increases C3 mRNA, C3 secretion and ASP
production [46]. While we have focused on the effects of
postprandial components on C3 and ASP production, many
factors, especially cytokines (TNFa, IL-6) and glucocorti-
coids have been shown to influence many of these proteins
including C3, B and adipsin and are proposed as potential
factors influencing C3 and adipsin in studies with anorectic
[48], obese [49] or coronary heart disease (CAD)-prone
[50] subjects.
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2. ASP, C3 and adipsin as circulating hormones
2.1. Human studies
Consequent to the publications on ASP function in
cultured adipocytes, increased interest has prompted a
number of studies on the plasma levels of ASP, C3 and/or
adipsin and the potential interactions with obesity, insulin
resistance, diabetes, hyperlipidemia and CAD. Before dis-
cussing these studies, one caveat to note is that other than
four of the studies, which range from 200 to 1000 subjects
[50–53], most of the studies have small sample sizes
(average 26, range 10–60 per group). Secondly, if ASP
has a paracrine, rather than an endocrine function, circulat-
ing levels may not always be sufficiently informative.
Certainly, while more detailed studies will clarify the
potential physiological significance of ASP and C3 in
related metabolic disorders (diabetes, hyperlipidemia and
CAD), these data are nonetheless thought provoking and
informative (as described in detail below).
While different assays (ELISA and RIA) have been used
for ASP determination, plasma concentrations in normal
healthy adults were similar, ranging from 10.3 to 58.1 nM
and, when all these studies were taken into account, the
weighted average was 28.3 nM (253 ng/ml) (n = 376 subjects
in 13 studies, author’s calculations, see Table 1 and refer-
ences). This contrasts strikingly with the concentration of the
precursor protein, complement C3, which is present at 225-
fold greater molar concentration than ASP. In the 15 studies
reviewed, plasma C3 in normal healthy adults ranged from
4.6 to 8.1 AM with a weighted average of 6.4 (author’s
calculations, n = 2812 subjects). Thus, at any given time, only
a relatively small proportion of C3 has been converted to
circulating ASP. Surprisingly, ASP levels were even lower
than those of adipsin, which is the initiating enzyme in the
cleavage process. Normal adipsin concentrations range from
49.0 to 66.7 nM (weighted average = 62.9 nM, n = 284,
author’s calculations, see Table 1).
While it has been suggested that there are gender differ-
ences in C3 and adipsin, the differences were small, and
contradictory from study to study perhaps due to the
phenotype of the subjects chosen [40,51,53–56]. In normal
weight subjects, there did not appear to be any difference in
plasma ASP between males and females [53].
2.2. Rodent studies
There is relatively little information on plasma levels of
any of the alternate complement proteins in rodents, and
even less information available regarding associations with
obesity, insulin or lipids. Certainly, C3 [57,58] and ASP [33]
levels all appear to be considerably lower in mice than in
humans. No quantitative assay of mouse adipsin has been
published. C3 levels vary from strain to strain [59], and while
they increase with age, there did not appear to be any gender
effect [57], again similar to humans. High fat diet [59],
cytokines [60] and obesity [61] were all associated with
increased plasma C3. While not statistically significant,
ASP (C3adesArg) was 50% higher in obese vs. lean mice,
and correlated to plasma triglyceride concentration [33].
Most of the results on adipsin derive from data on
genetically obese rodents. In ob/ob and db/db mice as well
as Zucker rats (all leptin pathway defective), and MSG-
treated mice, adipsin was decreased with obesity in most
[62–65] but not all [66] reports, although the adipsin
deficiency did not appear to be the cause of obesity [63].
Insulin, corticosteroids and cytokines, all of which are
increased in obesity, have been reported to suppress adipsin
[36,67,68], and may explain the decreased adipsin in rodent
obesity. On the other hand, lipodystrophic mice also have
reduced adipsin [69]. Decreased adipsin, however, does not
occur in gluttony-based obesity [70], and both a high-fat
diet [66] and caffeine [71] increased adipsin levels.
Based on the demonstrated cellular effects of ASP on
triglyceride synthesis, we examined the direct effect of ASP
on triglyceride clearance following a fat load in lean and
obese mice. In lean C57Bl/6 mice, intraperitoneal injection
of ASP reduced the triglyceride area under the curve (AUC)
by 40% [72]. Similarly, in ob/ob and db/db mice models
which are hypertriglyceridemic, hyperinsulinemic and
obese, ASP administration enhanced triglyceride clearance
by 2-fold [73]. There was also an overall decrease in the
plasma levels of NEFAs during the fat load, consistent with
increased uptake and storage into adipose tissues. Based on
these encouraging studies, we turned to examination of
murine models deficient in ASP.
3. ASP deficiency and KO models
3.1. ASP deficiency
ASP deficiency could result from a lack of C3, through a
genetic mutation, or, assuming that adipocyte ASP is only
Table 1
Fasting plasma ASP, C3, B and adipsin normal ranges
ASP C3 B Adipsin
28.3 nM
(10.3–58.1)
6.4 AM
(4.6–8.1)
62.9 nM
(49.0–66.7)
253 ng/ml
(92–518)
1.15 mg/ml
(0.83–1.45)
0.3 mg/ml 1.5 Ag/ml
(1.2–1.6)
n= 13 studies
(376 subjects)
[18,39,42,43,
48,53,119,124,
125,147,152,
180,210]
n= 15 studies
(2812 subjects)
[39,48,50–52,
55,56,118,122,
124,151,160,
211,212]
n= 1 study
[48]
n= 5 studies
(284 subjects)
[40,48,53,
128,204]
M=F [53] F>M [51,54],
M>F [55,56]
M>F [40],
M=F [53]
Fasting plasma ASP, C3, factor B and adipsin were measured by
immunoassay (as indicated). Averages presented are author’s calculations
where M=male and F = female.
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generated through the alternate complement pathway,
through an absence of any of the associated proteins
important in initiating the proximal step of the pathway.
Thus, a lack of factor B, adipsin (factor D) or properdin, the
convertase stabiliser, could also result in ASP deficiency.
Any of these genetic deficiencies, however, appear to be
extremely rare. According to Singer et al. [74], a total of 20
people with C3 deficiency has been reported from 1972 to
1992, 14 of them female. Deficiencies of properdin and
factor D are rare and no deficiency of factor B has as yet
been reported. By contrast, other complement protein defi-
ciencies, such as C2 deficiency, are ‘‘relatively common’’
[75].
Within the last year, there have been two reports of
families with alternate pathway deficiencies: properdin
deficiency [76] and factor D (adipsin) deficiency [77]. In
the family with factor D (adipsin) deficiency, most (60%) of
the homozygous subjects and all of those with partial
deficiency (heterozygous) had no history of infections.
Unfortunately, in both reports, there is no information
provided beyond that related to immunological function.
Consequently, it is difficult to ascertain whether the paucity
of cases recognised worldwide is a consequence of the
mutations being lethal or benign. The lack of human studies
and the availability of mice KOs has led to studies of ASP/
C3 in rodents, as described below.
3.2. Adipsin and factor B KO mice
With recent technological advances, there has been a
surge of murine models developed that present with a
deficiency (KO) or an excess (overexpression) of specific
proteins. A recent review highlights the phenotypes of
complement KOs [78], including, of interest to the present
discussion, factor C3- and B-deficient strains. Because ASP
is produced via the alternate pathway, deficiencies in either
C3, B or adipsin should result in lack of ASP.
It had been proposed that factor B mutation might be
lethal, since no human factor B deficiency has yet been
described. In fact, factor B-deficient mice are viable, fertile
and while manifesting absent alternative pathway activation
and decreased classical pathway activation, no overall
abnormalities of the immune system were detected [79],
but factor B appeared to play an unexpected role in auto-
immune disease [80]. Very recently, factor D/adipsin-defi-
cient mice have been produced [81]. No apparent abnormal
development or large change in body weight was detected
and serum concentrations of triglyceride, cholesterol and
NEFAs were reportedly not different. However, serum C3
levels were increased by 63% in D (adipsin)-deficient mice,
and cobra venom factor (CVF) treatment (a C3b analogue)
permitted the formation of an active C3 convertase contain-
ing intact B (instead of Bb), causing a profound and
reproducible cleavage of C3 [81] (and, theoretically, a
generation of ASP). The authors conclude that factor D is
not an absolute requirement for the generation of a CVF-
factor B convertase. By contrast, no such effect was docu-
mented in factor B-deficient mice [81].
3.3. Strain differences in C3 KO ASP-deficient mice
Two groups have created C3-deficient mice [82,83] and
they have been studied in infection, humoral immune
response, endotoxic shock and glomerulonephritis (for
review, see Ref. [78]). We have been particularly interested
in examining these C3 KO mice (obligate ASP deficient) for
disturbances in lipid metabolism, especially postprandially.
Our initial study, published in 1999, demonstrated a delayed
triglyceride clearance in male C3 KO mice [84]. No delay in
triglyceride clearance was noted in the female mice, who
manifested more rapid triglyceride clearance than males
overall [even in wild-type (WT) mice]. In a subsequent
study, we confirmed and extended those results, demonstrat-
ing increasingly delayed triglyceride clearance as the mice
aged, even on a high-fat diet [85].
By contrast, Wetsel et al. [86] demonstrated no such
difference in postprandial triglyceride in their breeding
colony of C3 KO mice, and in a review shortly afterwards
attempted to address these differences [87]. Their critical
evaluation was based on the premise that the two states,
ASP deficiency and ASP resistance should present with a
similar phenotype: hyperapoB. However, in the first
instance, mice do not normally manifest hyperapoB
(increased hepatic apolipoprotein B production) as dis-
cussed elsewhere [85], and, as discussed below, ASP
deficiency and ASP resistance will not necessarily present
with the same phenotype.
We speculated that, because both studies used mice
derived from a mixed breeding colony (C57Bl/6 and
129Sv), it was possible that the differing results were a
consequence of background strain. To resolve that ques-
tion, C3 KO mice were backcrossed seven generations to
each of the individual strains (C57Bl/6 and 129Sv). Plasma
variables tested in each of the strains are shown in Table 2.
There were no pronounced differences between KO and
WT in either strain for fasting plasma cholesterol or
Table 2
Characteristics of ASP-deficient (C3 knockout) mice according to strain
129Sv C57Bl/6
WT KO WT KO
n: (37) (52) (38) (26)
AGE (weeks) 20.9F 1.9 21.2F 2.1 28F 2.2 25.2F 2.9
Weight (g) 28.0F 1.0 26.1F 0.5* 31.0F 1.6 27.5F 2.1*
Cholesterol (mg/dl) 133F 4.2 127F 4.0 99F 4.9 91F 5.2
Triglyceride (mg/dl) 67.3F 5.5 56.9F 2.4* 65.3F 4.7 52.9F 4.2*
NEFA (mM) 0.90F 0.05 0.79F 0.02 1.22F 0.07 1.61F 0.11*
Glucose (mg/dl) 95.8F 5.2 83.3F 3.8* 156.8F 11.7 112.5F 6.1*
Insulin (ng/ml) 0.23F 0.03 0.24F 0.02 0.37F 0.09 0.33F 0.08
Fasting plasma was obtained and lipids and insulin measured as described
elsewhere [116]. Results are presented as averageF S.E.
*P< 0.05 for C3 knockout (KO) vs. wild type (WT).
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NEFA, other than a slight increase in fasting NEFA in
C57Bl/6 KO mice and small decreases in triglyceride.
Similarly, there was no difference in fasting insulin, but
a significant reduction in plasma glucose in KO in both
strains of mice.
On the other hand, there were pronounced strain differ-
ences in the postprandial triglyceride response, as shown in
Fig. 2. 129Sv male mice demonstrated a marked delay in
triglyceride clearance that was not seen in either Blk6 mice,
nor in 129Sv female mice (Table 3). This delay was almost
completely normalised with ASP administration (Fig. 1). As
this was the major difference between the two studies
[85,86], and the only strain difference that we found in
our parameters tested, we feel that strain difference likely
explains this. One might hypothesise that the C57Bl/6 mice
have a more efficient system for clearing dietary fat, perhaps
due to increased insulin sensitivity, lipoprotein activity, or
endogenous adipose tissue triglyceride synthetic capacity. It
is likely that ASP is not the only mechanism that influences
NEFA uptake, and redundant adaptive measures probably
compensate when ASP is absent.
There are many examples of strain influence on phe-
notypic expression of genetically modified mice (KO mice
or overexpressor mice). These differences likely arise
because of basic metabolic differences in the monogenic
WT strains of mice. Loss-of-function mutations, such as
fibronectin, apoE, eNOS, nNOS, leptin receptor (db/db),
have all been shown to demonstrate strain-specific pheno-
typic expression ranging from minor to severe (neonatal
death) effects. This issue has been carefully reviewed
recently by Sigmund [88]. Lipid and adipose tissue metab-
olism were different between C57Bl/6 and AKR mice
(both of which are obesity prone) and obesity-resistant
strains C3H, A/J, I and KsJ [89–100]. C57Bl/6 mice, for
example, are particularly susceptible to atherosclerosis,
diabetes and obesity (http://www.informatics.jax.org). In
studies that have compared C57Bl/6 and 129Sv strains
directly, there are differences in genetic taste traits, diet
preference, behaviour, electrophysiology and cerebral anat-
omy [101–110]. With respect to lipoproteins, 129Sv have
increased LDL cholesterol [111] and different LDL com-
position [112] compared to C57Bl/6. Apo AIV, Apo AI,
HDL cholesterol and HDL size are all increased in 129Sv
vs. C57Bl/6 [111,113–115].
It is important to note that we ascribe the differences seen
between KO and WT to the absence of ASP (and not C3) for
several reasons. First, although these mice lack both C3 and
ASP, there is no evidence to suggest that C3 plays a direct
role in lipid metabolism or fat storage, at least functionally
[6], while ASP has been shown to directly stimulate
triglyceride synthesis and storage [19]. Second, we have
previously shown that direct administration of ASP during a
fat load enhanced triglyceride clearance in normal mice
[72], as well as obese dyslipidemic mice such as ob/ob and
db/db [73]. Administration of ASP normalises triglyceride
and NEFA clearance in 129Sv male KO mice as shown here
in the present study. Thus, deficiency of ASP results in
delayed triglyceride clearance, and acute administration
reestablishes it.
3.4. ASP deficiency induces repartitioning of energy storage
and energy metabolism
Although we have also examined glucose, insulin, leptin,
growth curves, food intake and body composition in our
Table 3
Postprandial triglyceride and NEFA AUC in ASP-deficient (C3 knockout)
vs. WT in 129Sv and C57Bl/6 mice
129Sv C57Bl/6
WT KO WT KO
Triglyceride
Male 602F 96 1012F 160* 412F 41 411F 32
Female 465F 90 399F 17 359F 26 403F 14
NEFA
Male 5.91F 0.27 6.37F 0.32 5.91F 0.71 6.03F 0.18
Female 5.63F 0.23 5.99F 0.30 5.24F 0.31 9.73F 0.90*
Postprandial triglyceride (mg/dl) and (NEFAs) (mM) were measured over 6
h following administration of a fat load [85] and AUC calculated.
*P < 0.05.
Fig. 2. Postprandial triglyceride clearance in ASP-deficient (C3 / ) and WT in 129Sv (left panel) and C57Bl/6 (right panel) male mice. A fat load was
administered and blood samples taken serially over 6 h to measure plasma triglyceride [85]. In 129Sv ASP-deficient C3( / ) mice, an additional fat load was
conducted with ASP injected intraperitoneally at the start of the fat load.
K. Cianflone et al. / Biochimica et Biophysica Acta 1609 (2003) 127–143132
studies [84,85,116], this was not done in the study by Wetsel
et al. [86]. Interestingly, however, a deficiency in ASP
appears to have interesting and unanticipated effects on
adipose tissue mass, glucose metabolism and energy parti-
tioning. While the mechanism of these effects remains to be
elucidated in future studies, these three surprising findings
should be commented on.
First, ASP-deficient mice have reduced fat mass. This
has been documented indirectly, as reflected by reduced
body weight and decreased levels of plasma leptin (which
reflects adiposity) as well as by direct measurement of
adipose tissue mass [116]. Total fat mass was moderately
reduced in males [85], but markedly reduced by up to 60%
in females in all fat pads examined [116]. When tested over
a wide range in ages, body weight was consistently lower in
KO as was plasma leptin in both males and females
[85,116]. Again, this characteristic is pronounced in both
backcrossed strains of KO as clearly shown in Fig. 3.
Finally, even when placed on a high-fat diet, the C3 ( / )
ASP-deficient mice were resistant to diet-induced obesity,
and their body weight and plasma leptin remained consis-
tently lower than their WT littermates. The changes in
adipose tissue mass may be explained by reduced cell size
or a decreased number of adipocytes.
Based on fasting glucose, insulin and oral glucose
tolerance tests, ASP-deficient mice appear to be more
insulin sensitive [85,116], although this could be a conse-
quence of the relative leanness and protection against diet-
induced obesity. The reduced glucose levels in both 129Sv
and C57Bl/6 backcrossed strains of KO are also supportive
of that (Table 2).
Finally, the most intriguing finding was that although the
KO mice were leaner, food intake was much greater (up to
18% more caloric intake) with a normal fat absorption [85],
raising the question: Where does all this energy go? How
does the lack of ASP result in repartitioning and disposal of
excess energy? The balance of body energetics would
predict that any calories ingested, and not stored in some
form, would have to be expended as energy. The major
options are increased activity or enhanced thermogenesis.
Preliminary results presented at a recent meeting (late
breaking abstract, NAASO 2001) demonstrated increased
oxygen consumption in KO mice, but no changes in overall
activity, suggesting alternate disposal routes in the absence
of efficient adipose tissue storage.
While we ascribe the differences in the KO mice to the
absence of ASP rather than C3 (for the reasons outlined
above), it would be important to test this further in a mouse
that has C3, but not the capacity to generate ASP (such as in
a factor B or adipsin KO mouse). One fascinating area to
probe will be the control mechanisms between energy
storage and energy utilisation, and the mechanisms by
which lack of ASP results in a shift to increased oxidation.
4. Body weight, insulin resistance and ASP in humans
4.1. ASP, C3, B and adipsin in obesity and diabetes
Table 4 summarises studies in humans examining the
relationship between plasma ASP and the precursor proteins
C3, B and adipsin. Recently, there has been increasing
interest in ASP and C3, but the studies on factor B and
adipsin remain relatively few. Interestingly, linkage analysis
on factor B demonstrated an association of obesity to the
locus where factor B is found [117]. In a number of
independent studies, each of these proteins has been shown
to be increased in obesity, although not in all cases (for
details, see Table 4). For example, the increase in ASP
ranges from 58% to 400% normal. Overall, the increases in
C3 and adipsin were significant but modest, while the
relative increases in ASP tended to be greater. This is
consistent with the hypothesis that it is ASP that is the
key bioactive molecule, and the changes in C3 and adipsin
serve to influence the production of ASP. It should be
pointed out that the suggested link between C3 and obesity
is not new [118]. This idea has greater impact, however,
with the knowledge that adipose tissue may be an important
source of C3 and the recognition of the bioactivity of ASP.
ASP was increased to a greater extent in obese Caucasians
as compared to obese Pima Indians, although BMI were
comparable between the two groups [119]. In fact, obese
Pima also had lower plasma triglyceride and cholesterol
[119], but higher insulin [119] and adipsin [40]. The ethnic
difference in ASP remained even after adjustment for trigly-
ceride, NEFAs and percentage body fat. In Pima, fasting C3
concentration is also closely related to adiposity, fasting
insulin and especially insulin sensitivity andmay link obesity,
insulin resistance and possibly atherosclerosis [49]. In multi-
ple regression analysis with C3 as the dependent variable,
body fat, insulin action, gender and glucose tolerance status
were all independent determinants explaining a total of 80%
of the variance in C3 [49]. The low prevalence of dyslipide-
Fig. 3. Plasma leptin in ASP-deficient (C3 / ) and WT in 129Sv (left
panel) and C57Bl/6 (right panel) mice. Plasma leptin was measured by RIA
as described previously [116] at the indicated ages and is expressed as
nanograms per milliliterF S.E.
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mia in Pima has been linked to a region on chromosome 19p
which includes genes not only for lipid transport proteins, but
also includes the gene for C3 [120].
All of these factors (ASP, C3, B and adipsin) have also
been shown to be significantly increased in Type II
(NIDDM) diabetes and also in some studies of Type I
diabetes (Table 4). As diabetes is often associated with
obesity, this may be a confounding factor. For example,
ASP is increased in NIDDM [39], but only to a level
comparable to non-diabetic subjects of matched weight
[39,121]. However, even in non-obese Type I diabetics,
plasma C3 levels are increased, and this is further exacer-
bated by hypertension [122]. ASP correlated with whole-
body glucose and lipid metabolism in nondiabetics, but not
in diabetics [39]. It was suggested that the metabolic
disturbances in diabetes overcame the regulatory role of
ASP, explaining the loss of association [39].
4.2. Effect of weight loss, weight gain and exercise
Considering the increases in ASP, C3, adipsin and factor
B with obesity, it is perhaps not surprising that these factors
changed with weight loss (Table 4) or exercise. In two
separate studies with moderately trained athletes, ASP/
C3adesArg levels were 2.7–6.1 nM [123] and 21.3 nM
[124] at baseline, and increased acutely by 67% [123] and
29% [124] during a timed run (0.5–2.5 h), then returned to
baseline shortly afterwards. While there was no exercise-
induced change in C3, baseline values were lower in the
athletes compared to controls (frequency distribution was
significantly shifted to the left) [124]. In a much larger study
that included 1090 middle-aged men, there was an inverse
relationship between physical activity and C3, an associa-
tion that was independent of the relationship to other plasma
variables (lipids, glucose, insulin) [50].
ASP decreased with weight loss in obese subjects [56],
and normal weight post-obese women had normal levels of
ASP [125]. Similarly, plasma C3 decreased with weight loss
[48,118,126,127] and was decreased in subjects with ano-
rexia nervosa [48]. Both adipsin and factor B decreased with
weight loss [48,128], and were decreased in anorexia
nervosa [40,48] and increased toward normal levels with
weight gain in subjects with anorexia nervosa [40,48]. One
study examined classical complement pathway components
as well and concluded that there was little change in the
components of the classical pathway, and that alternative
complement components were preferentially affected by
weight loss in both anorectics and obese dieters [48]. Thus,
overall, all of these factors change in concert with changes
in body weight (and accordingly fat mass), suggesting that
at least one major influence on plasma levels of ASP and C3
is adipose tissue mass.
4.3. Lipodystrophy
Related to the issue of weight loss, there are some
interesting changes in ASP pathway proteins in partial
lipodystrophy (PLD). PLD can be divided into congenital
and acquired forms. Congenital PLD appears to be heredi-
tary, is X-linked and appears to be lethal in the hemizygous
state [129]. Congenital PLD is associated with increased
insulin, NEFAs, insulin resistance and sometimes diabetes
[130]. On the other hand, acquired PLD develops later, but
still in childhood and occurs more often in females than
males [131]. Acquired PLD has consistently been reported
to be associated with striking decreases in C3 and the
presence of C3 nephritic factor (C3NeF) which is not found
in normal individuals [132] (Table 4). For example, Ipp
[133] reported 6 of 7 patients had reduced C3 and Sissons et
al. [131] reported the same phenomenon in 17 of 21
patients. More recently, Tanuma et al. [134] reported that
all patients had only 10% of normal C3 levels and Skattum et
al. [135] reported that 20 of 25 had reduced C3. On the other
hand, other plasma complement proteins (such as B, proper-
Table 4
Effects of weight gain and weight loss on ASP, C3, B and adipsin
ASP C3 B Adipsin
Obesity z 58% to 4 normal [39,53,119,210] z 11–25% [48,50,118] z (48%) [48] z 14–64% [40,53,128,204]
nc [43] nc [39,211,212] nc [48]
Pima <Caucasian [119] Pima>Caucasian [40]
F>M [53]
NIDDM z 25% [39] z [211,213] z [214] z 36% [204,214]
NIDDM=Obese [39,121] nc [39]
IDDM z 24% [122,213,214] z [214] z [214]
Weight loss (in obese) #  45% [210] #  12% to  32% [48,126,127,118] #  12% [48] nc [48,214]
post-obese = normal [125]
Anorexia nervosa nc [48] #  20% [48] #  17% [48] #  19% to  40% [40,48]
Weight gain nc [48] z 16% [48] 38% [48] z 22% [40,48]
#  28% AIDS [40]
Lipodystrophy (LD) # acquired LD [131,133–135] nc partial LD [40]
nc hereditary LD #  46% total LD [40]
Fasting plasma ASP, C3, factor B and adipsin were measured by immunoassay. Abbreviations are: NIDDM (non-insulin-dependent diabetes mellitus), IDDM
(insulin-dependent diabetes mellitus), F (female), M (male), LD (lipodystrophy), nc (no change vs. control).
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din, C2, C4, C5 and C6) appeared to be normal [131,
134,136]. While there is little information on insulin and
plasma lipids in acquired PLD, it has been shown in one case
to be associated with fatty liver [136].
C3 nephritic factor has been shown to be an IgG
autoantibody reacting with a neoantigen exposed on the
surface of the alternative pathway convertase, C3bBb,
which is stabilised and rendered resistant to the physiolog-
ical control proteins, factors H and I [137]. This results in
hypercatabolism and chronic depletion of C3 [138]. This
reaction is specific to the alternative pathway and does not
occur in the classical pathway [133]. A recent report has
shown that adipocytes are lysed by C3NeF-containing
serum, but not normal serum, suggesting that local produc-
tion of C3/B/adipsin by adipocytes (which produces ASP)
in the presence of C3NeF results in acute dysregulation of
alternate complement activation in the microenvironment of
the adipocytes, and these cells are targeted for lysis by the
terminal complement components [139].
4.4. Effect of insulin sensitizer pharmacological therapy on
ASP and C3
Three recent studies have examined the changes in ASP
and/or C3 with pharmacological treatment in diabetics with
either sulfonylurea drugs (glibenclamide) [121,140] or with
thiazolidinediones (TZD) (troglitazone and pioglitazone)
[54,140]. In a study by Ebeling et al. [54], following
treatment for 16 weeks of older diabetic subjects, troglita-
zone decreased C3 as well as glucose and insulin require-
ments. This effect was selective for C3, as other acute-phase
proteins (alpha-1 antitrypsin, ceruloplasmin, C-reactive pro-
tein and haptoglobin) were not affected. There were no
significant changes in any plasma lipids or apolipoprotein
B, but apolipoprotein A1 decreased. While baseline C3
correlated with BMI, C3 decreased with treatment while
BMI increased significantly.
A more recent study by this same group has examined
the effects of a TZD (pioglitazone) and a sulfonylurea drug
(glibenclamide) on both ASP and C3 in diabetics [140]. In
contrast to the previous study, this TZD did not have an
effect on plasma C3; however, there was a significant
decrease in C3 with glibenclamide treatment. Both treat-
ments produced a decrease in glucose and HbA1c, but a
slight increase in plasma cholesterol with no effect on other
lipids. Again, while C3 correlated with BMI, this did not
explain the change because the decrease in C3 with treat-
ment was accompanied by an increase in BMI. There was a
trend for changes in ASP, but the individual group effects
were not significant. However, the change in HbA1c with
treatment, which reflects glycemic control, correlated pos-
itively with the change in ASP. In fact, the change in HbA1c
was best explained by changes in ASP and insulin (neg-
ative) that together explained 33% of the variation.
Rieusset et al. [141] examined the acute effects of
rosiglitazone on gene expression in human adipocytes.
Although a short-term (4 h) incubation increased PI3 kinase,
UCP2 and decreased leptin mRNA, there was no effect on
ASP (C3 mRNA). Similarly, there was no effect on IRS1,
Glut4, lipoprotein lipase, HSL or PPARg. Thus, the effects
may be different for each TZD, or may require longer
incubation times.
Another study has also reported effects of glibenclamide
on plasma ASP [121]. Following 4 months of treatment in
poorly controlled diabetic obese women, there was a sig-
nificant decrease in glucose, HbA1c, leptin and plasma
cholesterol but, by contrast, a significant 30% increase in
ASP. Neither ASP nor leptin correlated with any of the
fasting plasma variables examined (glucose, insulin or
lipids). Only leptin correlated with BMI. While fasting
ASP values increased with improved glycemic control, the
lack of correlation with measured variables suggests that
other factors may play a role in influencing ASP levels. The
authors suggest that glibenclamide, through interaction with
the sulfonylurea receptor 1, which is expressed in human
adipose tissue [142], could potentially increase ASP pro-
duction. This receptor influences lipogenesis and lipolysis
through phosphoinositide specific phospholipase C and
tyrosine phosphorylation [143,144]. Thus, this effect on
ASP could be mediated by (i) increasing insulin sensitivity
because insulin increases C3 production and thus ASP
[44,45]; or by (ii) inhibiting TNFa production [145],
preventing TNFa suppression of adipsin secretion [146], a
key enzyme for cleavage of C3 to ASP; or (iii) as a result of
a primary drug effect on ASP production.
4.5. Correlations of ASP, C3, B and adipsin with body size
and glucose/insulin
Many of these studies have examined the correlations of
ASP, C3 and adipsin with parameters that reflect body size
or insulin/glucose homeostasis as summarised in Table 5. A
number of studies have demonstrated that plasma ASP
correlates positively with various indices of body size. This
includes BMI and percentage ideal body weight [39,53,119,
147], waist to thigh or waist to hip ratio [39,147], total fat
mass or percentage body fat [39,49,119]. Not all studies,
however, have demonstrated this relation [121]. In the same
way, there are a number of studies that have demonstrated
similar associations with C3 (n = 9 studies) and adipsin (n = 5
studies), while only 1 study [48] has examined this with
factor B (see Table 5). Certainly, however, the evidence is
very consistent.
Studies with obese, poorly controlled diabetic and treated
diabetic subjects lend themselves to correlations with insu-
lin, glucose and associated parameters. As summarised in
Table 5, ASP was associated with insulin and glucose
disposal rate in some [39,147] but not all studies [49,121].
ASP was also associated with changes that reflect diabetic
control following treatment [140]. Three studies with adip-
sin also suggested a correlation with insulin. Similarly, C3
correlated significantly with insulin, glucose and glucose
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disposal rate, as well as factors related to diabetic treatment.
As commented on by Weyer et al. [49], it remains unknown
whether the strong association of C3 with obesity is a
consequence of increased adipose tissue production or due
to secondary mechanisms involving hepatic C3 production.
The association of increased C3 with insulin resistance may
be a cause or consequence of effects mediated through
cytokines such as TNFa or IL-6 [148] or glucocorticoids
[149]. Interestingly, while glucocorticoids stimulate C3
production, they inhibit adipsin production [67].
5. ASP resistance and cardiovascular disease
5.1. Associations of ASP and C3 with cardiovascular
disease, hypertension and hyperlipidemia
Only C3 and to a lesser extent ASP have been examined
with respect to CAD, hypertension or hyperlipidemia. In
two studies with hypertensive subjects, it was demonstrated
that C3 specifically, but none of the other immunologic
factors tested, was higher in hypertensive subjects [150]. In
a larger study with 350 women with no known CAD,
divided according to hypertensive and diabetic status,
increased C3 was shown to be associated with hypertension
and diabetes (with an additive effect) [122].
In two large studies by Muscari et al. [50,51] (n = 860 and
1090 subjects), C3 was shown to be a powerful predictor of
myocardial infarction, especially in men [51]. None of the
other immunologic variables examined was found to be
independently associated with ischemic events. This relation-
ship persisted retrospectively and, as noted by the authors,
was more significant than any other association of traditional
risk factors with myocardial infarction [50]. Of the many
variables associated with C3 (Tables 5 and 6), insulin was the
main covariate, suggesting that C3 is a marker of metabolic
imbalance coinciding with insulin resistance [50].
C3 is also associated with various forms of hyperlipide-
mia, even in the absence of atherosclerosis [151]. Specifi-
cally, Type IIb (but not IIa), Type IV hyperlipidemia [151]
and familial combined hyperlipidemia (FCHL) [55,147], all
of which are characterised by increased fasting plasma
triglyceride and/or cholesterol, have been shown to have
increased C3. While most of these studies have demonstra-
ted an association of C3 with BMI [50,51,55,147], the C3
increases were independent of the effect of BMI [50,55,151]
and were strongly associated with plasma triglycerides,
cholesterol, LDL cholesterol [50,51,55,147,151] and an
especially striking correlation with apolipoprotein B
(r = 0.64 and 0.77) [55,147].
There are only two studies examining ASP in similar
subjects: one in patients with CAD [152] and one in subjects
with FCHL [147]. ASP was increased overall in subjects
with CAD, especially in those with increased plasma
triglyceride and/or cholesterol as characterised by increased
plasma apolipoprotein B levels (HyperapoB) [152]. While
subjects with FCHL have increased ASP compared to
normal healthy controls [147], there appeared to be no
difference between hypertriglyceridemic FCHL and normo-
triglyceridemic FCHL [147]. In contrast, with C3, there was
a further increase in hypertriglyceridemic FCHL compared
to normotriglyceridemic FCHL [55].
A very recent study has examined both C3 and ASP in
subjects with nephrotic syndrome [153]. Nephrotic syn-
drome is characterised by increased hepatic protein and
lipoprotein synthesis. Interestingly, in a group of 25 sub-
jects, fasting ASP was increased 4.5-fold, with no corre-
sponding increase in either C3 or leptin. This was accom-
Table 5
Correlation of ASP, C3, B and adipsin with body size indices and glucose homeostasis
ASP C3 Adipsin
BMI or percentage ideal body weight + ve [39,53,119,147] + ve [48–51,54,55,140,147,160] + ve [40,53,128,204]
ns [49,121] also + ve factor B [48]
Waist/hip or waist/thigh + ve [39,147] + ve [49,147,160] + ve [204]
ns [49,121]
Percentage fat or total fatness + ve [39,49,119] + ve [49] + ve [40,128]
Change in body weight + ve change [48] + ve change in adipsin and factor B [48]
Leptin + ve [128]
Age ns [40]
Insulin or insulin AUC + ve [39,147] + ve [49,50,55,147,160] + ve [40,128,204]
ns [49,121]
Glucose or glucose AUC ns [49,121,147] + ve [49,50,55,147,160,215] ns [204]
GDR or M  ve [39]  ve [49]
ns [49]
Other + ve HbA1c [140] + ve HbA1c [54] + ve PAI-1, tPa [204]
+ ve Antitrypsin [140] + ve Antitrypsin [140]
C-reactive protein [140]
ASP, C3, factor B and adipsin were measured in the indicated studies by immunoassay and correlated to the various indices. Abbreviations are: + ve
(significant positive correlation),  ve (significant negative correlation), ns (no significant correlation), GDR (glucose disposal rate), M (HOMA index of
insulin sensitivity).
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panied by a striking increase in total cholesterol, triglycer-
ides, apolipoprotein B and LDL cholesterol. The increase in
ASP cannot be simply a consequence of up-regulated
hepatic protein secretion, because the precursor C3, which
can be synthesised by the liver, was not significantly
increased.
5.2. Correlations of C3 and ASP to lipids
As summarised in Table 6, a number of studies have
shown associations of C3 and ASP with lipids in varied
subject groups including normal healthy controls, obese,
diabetic and hyperlipidemic subjects. Overwhelmingly, C3
correlates positively with plasma triglycerides, total cho-
lesterol, LDL cholesterol, apolipoprotein B and NEFAs,
with significant negative correlations with HDL choles-
terol. Several studies show similar associations with ASP
(Table 6), although not in all studies [121]. There are
only four studies with adipsin. A genome wide linkage
analysis in a study with a large number of subjects
suggested an association of blood pressure to adipsin
locus [154].
5.3. HyperapoB: in vivo to in vitro functionality
While the dyslipidemia which is common to insulin
resistance, syndrome X and CAD likely has multiple
causes [155–157], it has been proposed that abnormal
fatty acid fluxes to the liver may be one driving
component [158]. One interesting link supporting the
notion of ASP resistance has been demonstrated in
HyperapoB subjects tested for ASP response. Cells from
HyperapoB subjects with increased plasma ASP appear
to have a reduced response to ASP [18], those with
normal plasma ASP responded normally to ASP when
tested in cell culture [18], suggesting that a high plasma
ASP might be a marker of ASP resistance. In some
patients, reduced adipose tissue response to ASP could
result in increased hepatic fatty acid flux, which stim-
ulates increased apolipoprotein B production (both
VLDL and LDL) [159], explaining the associations
between C3, ASP, lipids and insulin parameters. In fact
this hypothesis of ‘‘ASP resistance’’ in adipose tissue,
which we have proposed [159], is seconded by several
authors in their studies [39,121,153,160] although not by
all [147].
6. Relationship of C3 with ASP
Surprisingly, considering the number of studies on C3
and ASP in the last few years, there are few studies that
have actually examined both proteins, and even fewer that
have directly compared the levels of ASP to C3, especially
considering that ASP is the product of C3 cleavage. In a
study by Ylitalo et al. [147], a strong familial component to
both C3 and ASP was identified. Thus, C3 demonstrated a
significant sibling–sibling association, and ASP a signifi-
cant parent–offspring correlation. However, in spite of the
association of C3 with CAD, there was no association
between C3 and familial history of myocardial infarction,
suggesting that the association of C3 to CAD is not solely
due to hereditary linkages [50]. In those studies that have
compared both C3 and ASP (Table 6), while one study
showed strong correlations (up to r = 0.92) [153], most are
not at all strong. In fact, in two studies, there was no
significant correlation at all, suggesting that determination
of ASP concentration will depend not only on production of
C3, but also on factors which regulate conversion of C3 to
ASP.
6.1. Conversion of C3 to ASP and C3 polymorphisms
The conversion of C3 to ASP requires multiple factors.
Adipsin is needed to cleave factor B to generate the
membrane-attached active convertase (C3bBb), which in
Table 6
Association of ASP and C3 with dyslipidemia and CAD
ASP C3 Adipsin
CAD z [152] z [51,52,160]
+ ve [39,51]
Hypertension
(blood pressure)
ns [121] z [122,150]
+ ve [50,51,150,
linkage
analysis
160] + ve [154]
Hyperlipidemia z H apoB
[152]
z Type II, IV
[151]
z FCHL
[147]
z FCHL [55]
HTg FCHL>
HTg FCHL=
NTg FCHL
[147]
NTg FCHL
[55]
Triglyceride + ve [39,53,119,
147,152]
+ ve [50,55,56,
147,150,151,160]
+ ve [128]
ns [204]
 ve [216]
ns [121]
Non-esterified
fatty acids
+ ve [39,53,119,
210]
+ ve [55,147] + ve [53]
ns [147]
 ve [216]
Apolipoprotein B + ve [147] + ve [55,147,160] + ve [53]
ns [39,121]
Total cholesterol ns [119,121,147] + ve [50,51,55,56,
147,151,160]
LDL cholesterol  ve [216] + ve [55,160]
ns [121] + ve Lp (a) [52]
HDL cholesterol  ve [39,147]  ve [50,55,147]
ns [121]
Correlation of ASP with C3:
+ ve r = 0.38 [147], 0.43 [49], 0.58 [39], 0.68 and 0.92 [153] and ns
[140,180]
ASP and C3 were measured by immunoassay and correlated to the various
indices. Abbreviations are: + ve (significant positive correlation),  ve
(significant negative correlation), ns (no significant correlation), CAD
(coronary artery disease), HapoB (hyperapobetalipoproteinemia), FCHL
(familial combined hyperlipidemia), HTg (hyper-triglyceridemia), NTg
(normo-triglyceridemia), Lp(a) (lipoprotein (a)).
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turn is stabilised by properdin, but destabilised by factors H
and I [161]. Thus, the concentration of any one of these
factors may determine the overall kinetics of the reaction.
However, other than the concentration of any one of
these factors, especially C3, the structure of the proteins
themselves may well influence ASP production. It has long
been recognised that C3 polymorphisms occur predomi-
nantly in two forms: C3F and C3S, termed fast and slow
according to migration on electrophoretic gels [162]. The
molecular basis for this difference was resolved by Botto et
al. [163] who demonstrated a C to G shift at bp 364 in exon
3 leading to an Arg (+) to Gly (neutral) shift in amino acid
102. The frequency of C3S is much more common than
C3F, especially in non-Caucasian populations with frequen-
cies of 0.79, 0.95, 0.97 and 0.99 in Caucasian, African
American, SA Indian and Asian, respectively [74]. A similar
polymorphism distribution has been noted in mice (C3A
and C3B), as in humans (C3S and C3F), and this is
associated with differences in functional activation [164]
and, possibly, with strain differences [165].
There is no evidence that the variant of C3 influences
plasma C3 levels [162,166–168], but it has been suggested
that C3F may have increased activation rates [162,164,169]
which might result in increased plasma ASP. C3F also has
increased binding to its clearance receptor (CR) [163,164,
166] although both these differences have not been con-
firmed in all studies [166,169,170].
Correlation studies suggest that the C3F variant has an
increased association with atherosclerosis and hypertension
[171–174] and with hypercholesterolemia [175,176] but not
with Type I or Type II diabetes [177]. In addition, C3F is
associated with PLD [74,163,178] and in one study, it was
demonstrated that PLD was associated with a change in the
distribution with proportionally less serum C3F present in
affected individuals [179]. It remains to be seen in future
studies whether the generation of ASP is influenced not only
by C3 levels, but also by C3 polymorphisms, as well as
other factors.
6.2. Postprandial ASP and C3
Considering the functional role proposed for ASP, and
the correlation between ASP and C3 with plasma triglycer-
ides and other lipids (Table 6), examination of postprandial
ASP is natural. To date, there are five studies on postpran-
dial ASP and three on postprandial plasma C3 in human
subjects. While the fat load meal from study to study varies
in daily calorie allotment (20–60%), and in fat content (28–
100 g fat), the results are similar.
Two studies on C3 [39,180] reported no change, and
another study reported a small (24%) but significant
increase in C3 at 2–6 h postprandially [160]. As the authors
point out [160], because systemic ASP levels do not change
postprandially, suggesting that ASP production is a local
phenomenon, they have focused on postprandial C3
changes. While our initial study reported much higher levels
of plasma ASP which increased postprandially [181], we
later realised that this was due to antibody cross-reaction
with C3 [182] and, in retrospect, would be consistent with
the present findings by Halkes et al. on C3.
Fat load studies demonstrate either no change in plasma
ASP [39,147,180] or a slight tendency for ASP to decrease
over time [119,125]. Only one study with a very high fat
load (100 g) demonstrated a significant linear positive trend
vs. time [125]. In a recent study with post-obese subjects
[125], plasma ASP tended to be lower in post-obese vs.
controls, and there was a significant drop in ASP in both
groups over the 8 h. In fat loads with obese diabetic
subjects, fasting and postprandial ASP were consistently
higher in obese diabetics vs. control [39,119], but not
different from obese [39]. Parallel determinations of C3 in
these patients showed no difference in any group [39].
While there was no postprandial change in ASP, fasting
ASP did correlate with postprandial triglyceride and NEFA
AUC [39]. Interestingly, while obese Caucasians had mark-
edly increased fasting and postprandial levels compared to
controls, in Pima subjects, the differences between obese
and controls were less pronounced [119]. In this last study
[119], there was a significant decrease in plasma ASP over
the 6 h in all subject groups (control and obese, Caucasian
and Pima). The authors suggest that the observed decrease
in ASP concentrations reflects either an underlying diurnal
rhythm as is seen with leptin [183,184] or that postpran-
dially, ASP is shifted from the intravascular to the interstitial
compartment where it exerts its biologic action.
In FCHL subjects, fasting ASP was significantly higher
than controls, and there was no consistent change in ASP
over the fat load. Although there was a trend to differences
in incremental AUC between FCHL (average 149 ng/ml/h)
and controls (26 ng/ml/h), the high variation precluded
significance. The effects of hyperlipidemic treatment on
fasting and postprandial C3 have been examined in an
interesting study by Halkes et al. [160]. In a group of
normolipidemic non-obese CAD patients, plasma C3 and
postprandial C3 AUC were significantly increased vs. con-
trol subjects. Following 5 weeks of treatment with simvas-
tatin (an HMGCoA reductase inhibitor), there were
decreases in fasting plasma cholesterol, LDL cholesterol,
triglyceride, and apolipoprotein B with no change in either
glucose, insulin or BMI. There was also a significant drop in
both fasting C3 and postprandial C3 AUC with treatment.
Fasting C3 and postprandial C3 correlated with triglyceride
AUC. With treatment, the drop in triglyceride AUC was the
only variable that correlated with the drop in fasting C3.
Plasma C3 was also significantly associated with several
features of the insulin resistance syndrome (glucose, trigly-
ceride, insulin, BMI, blood pressure and waist circumfer-
ence), consistent with the studies above [50,51]. Treatment
with statins not only increases LDL clearance, but also
decreases VLDL production [185] and enhances chylomi-
cron clearance [186,187]. The decreased chylomicron con-
centration may reduce the drive for C3 and ASP production;
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at least this is a powerful stimulus to both C3 and ASP
secretion in vitro from human adipocytes [44–46].
7. Integration of CAD, insulin resistance, ASP and
complement
7.1. ASP deficiency vs. ASP resistance
Teleologically, then, a dysfunctional ASP pathway might
result from either an absence of ASP (ASP deficiency), or a
decrease in response to the biologic action of ASP (ASP
resistance). This is the same argument that might apply to
insulin or leptin. Both a lack of leptin (rare mutations) [188]
and the proposed leptin resistance [189] are associated with
obesity. Similarly, a lack of insulin (Type I diabetes) or
insulin resistance (Type II diabetes) unquestionably both
result in disturbances of glucose homeostasis. However, the
remaining metabolic profiles are not necessarily the same.
Insulin-resistant Type II diabetes is associated with obesity,
especially visceral obesity, increased NEFAs, dyslipidemia
and HyperapoB [190]. Type I diabetes is not. By analogy,
then, although we cannot predict with certainty the pheno-
type of ASP deficiency vs. ASP resistance, we should not
necessarily expect the metabolic profiles to be identical.
Hypothetically, based on studies in C3 KO ASP-deficient
mice [84,85,116], one might expect ASP-deficient subjects
to be lean but with the potential for delayed triglyceride
synthesis. Again, hypothetically, ASP resistance by exten-
sion from responses in HSF from hyperapoB subjects, could
demonstrate reduced response to ASP coupled with
increased plasma ASP and apoB [18].
7.2. Adipose tissue, liver and arterial wall
This review has focused on the association of ASP and
C3 with CAD and associated risk factors, especially insulin
and insulin resistance, with a focus on the links to adipose
tissue metabolism. On the other hand, the interactions of C3
and complement (and thus ASP) with liver metabolism and
arterial wall milieu cannot be ignored, as these may also
contribute to the described associations with CAD and
diabetes. Granted, it is difficult to identify the relative
contributions of all of these circulating factors (C3, ASP,
lipids, glucose, insulin) on individual tissues (adipose tissue,
liver and arterial wall) to determine the contributions to
metabolic disturbances (obesity, insulin resistance, dyslipi-
demia and atherosclerosis).
The cycle of association between increased C3, CAD
and lipids [50,51,56] may simply reflect the fact that
these lipid risk factors induce atherosclerosis. In the
arterial wall, this leads to increased activated macrophages
in atherosclerotic plaques which in turn can produce C3
[191]. C3 has been identified in extracts from athero-
sclerotic plaques [192,193], and it has been suggested that
a cholesterol–albumin-rich extract from plaques may
actually activate complements [194]. As pointed out by
Ylitalo et al. [147], ‘‘it remains unclear whether C3 is an
independent risk factor or a surrogate marker of vascular
inflammation and atherosclerosis’’. On the other hand,
although C3 appears to bind to both LDL and Lp(a)
[195], neither these nor oxidised LDL, had any effect on
complement activation [192,194]. While complement
receptors CR1 and CR3 have been identified by immu-
nological techniques in the arterial wall, so have many
other proteins such as apolipoprotein B, albumin, a2
macroglobulin, HDL and a1 antitrypsin [192,196–198],
suggesting a nonspecific infiltration of plasma proteins
into damaged arterial wall.
The associations of C3 and ASP with CAD and dyslipide-
mia could also reflect secondary mechanisms involving hep-
atic C3 production. Certainly the liver has long been proposed
as a major source of C3 [27]. As discussed by Muscari et al.
[50], while there is a strong association of C3 with insulin,
other acute-phase proteins (PAI-1, fibrinogen and C-reactive
protein) also correlatewith insulin [199–201]. Thismay be an
effect of cytokines (such as TNFa) which induce both acute-
phase protein synthesis in the liver and insulin resistance.
In a recent commentary, Yudkin et al. [202] proposed that the
source of such cytokines may actually be the adipose tissue.
Insulin can inhibit the cytokine-mediated effects on hepatic
synthesis of acute-phase proteins including C3 [203], an
effect that might be abrogated in insulin resistance. Weyer
et al. [49] also suggest direct links between insulin resistance
and C3 production in hepatic and adipose tissue.
In the study byMuscari et al. [50], in multivariate analysis,
the relationship between risk factors and C3 persisted after
the addition of insulin to the independent variables. Blood
pressure and glucose were better predicted by C3 than by
insulin, leading the authors to comment that ‘‘serumC3might
be a better marker of insulin resistance than insulin itself’’
[50]. Similar considerations apply to adipsin and ASP. There
are strong associations between adipsin and PAI-1 as well as
other related factors (BMI, insulin and triglycerides).
Changes following weight loss might be explained by either
hepatic or adipose tissue modulation of PAI-1 production
[128,204]. In the study by Ebeling et al. [140], while ASP
correlated strongly with glycemic improvement in treatment
of diabetics, ASP also correlated with a number of acute-
phase proteins, which are characteristically increased in Type
II diabetes. As the authors point out, the correlation between
changes in inflammatory factors and glycemia was not
stronger than the decreases in HbA1c and ASP, suggesting
other mechanisms of association.
One intriguing point to be addressed is the apparent
overlap between the immune system and adipose biology.
Which one actually originated first is an important question.
Evolutionarily, C3 appears to be present in organisms that
lack a complement lysis pathway. This immune/adipose
cross talk is true not only for ASP, but also for adipsin
(factor D), TNFa, angiotensin II, many interleukins, TGFh,
all of which are produced by adipocytes, influence adipo-
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genesis [205] yet have well-recognised roles in immune (or
other) systems. A number of review articles have com-
mented on this duality [206–209]. In fact, many proteins
have been shown to fulfill dual roles, depending on tissue
expression. Thus, we cannot completely rule out the
involvement of hepatic and arterial wall immune responses
in the associations of C3/ASP with CAD, obesity and
metabolic dysfunction.
8. Conclusion and future directions
In this review, we have summarised recently published
data on ASP and C3, and attempted to present the cellular,
rodent and human studies in an integrated physiological
model. In cellular studies, ASP increases fat storage through
increased triglyceride synthesis and decreased intracellular
lipolysis. In rodent models, absence of ASP results in
reduced adipose tissue; obesity is associated with increased
ASP. Evidence is accumulating in humans which supports a
role for ASP and C3 in adipose tissue function and main-
tenance of metabolic homeostasis. This is particularly noted
in the links between ASP and C3 with diabetes and CAD
and well-recognised risk factors such as lipids and glucose/
insulin. While the etiology of many of these relationships is
not yet understood, future studies in understanding the
signalling mechanisms of ASP in health and disease will
lead us in that direction.
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